A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2018
Price : $35 *
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 07 Oct 2018 Results of a combined resistance analyses from this and three other phase 2b studies, presented at the IDWeek 2018.
- 28 Apr 2017 Status changed from recruiting to completed.
- 09 May 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.